EADV 2022: Dupixent shows sustained efficacy across anatomical regions in children
Dupixent is proving to be very efficacious even in the youngest of patients and is expected to dominate its market.
By
Immunology
Latest in
Immunology
Pipeline Moves: Novartis completes Phase II Sjögren’s syndrome trial, advancement prospects jump
The Clinical Trials Arena team also reviews a trial suspension in leishmaniasis, a termination in lymphoma and trial completions in…
By
Pipeline Moves: Nektar terminates Phase I/II cancer trial, further study shot in seven indications drop
Further investigations of peanut allergy and traumatic brain injury assets also reviewed after study terminations.
By
Should rheumatoid arthritis trials exclude patients based on their Covid-19 vaccine status?
There are 166 rheumatoid arthritis studies in the planning stage, with four ongoing or planned trials with criteria specifically noting…
By
Halia doses first subject in Phase I trial of chronic inflammation asset
The trial will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of HT-6184 in up to 32 healthy subjects.
Obesity in adolescents increases the risk of type 1 diabetes
T1D is more severe than type 2 diabetes and can damage major organs.
By
AstraZeneca doses first subjects in Phase III lupus nephritis trial
The trial will assess the safety and efficacy of anifrolumab versus placebo in adults with active Class III or IV…
Inmagene receives FDA clearance for Phase I trial of immunological disease BTK inhibitor asset
A small molecule BTK inhibitor, IMG-004 is being developed to potentially treat immunological diseases.